EA202092908A1 - Модуляторы ионных каналов - Google Patents

Модуляторы ионных каналов

Info

Publication number
EA202092908A1
EA202092908A1 EA202092908A EA202092908A EA202092908A1 EA 202092908 A1 EA202092908 A1 EA 202092908A1 EA 202092908 A EA202092908 A EA 202092908A EA 202092908 A EA202092908 A EA 202092908A EA 202092908 A1 EA202092908 A1 EA 202092908A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ion channel
disease
treating
condition associated
channel modulators
Prior art date
Application number
EA202092908A
Other languages
English (en)
Inventor
Эндрю Марк Гриффин
Брайан Эдвард Маррон
Габриэль МАРТИНЕС БОТЕЛЬЯ
Киран РЕДДИ
Мэрион Уитманн
Original Assignee
Праксис Пресижн Медсинз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Праксис Пресижн Медсинз, Инк. filed Critical Праксис Пресижн Медсинз, Инк.
Priority claimed from PCT/US2019/034653 external-priority patent/WO2019232209A1/en
Publication of EA202092908A1 publication Critical patent/EA202092908A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Данное изобретение относится, в частности, к конденсированным гетероарильным соединениям и композициям, применимым для предотвращения и/или лечения заболевания или состояния, связанного с аберрантной функцией потенциал-управляемого натриевого ионного канала, например, аномальным поздним/постоянным натриевым током. В данном документе также представлены способы лечения заболевания или состояния, связанного с аберрантной функцией натриевого ионного канала, включая неврологические расстройства (например, синдром Драве, эпилепсия), боль и нервно-мышечные расстройства.
EA202092908A 2018-09-28 2019-05-30 Модуляторы ионных каналов EA202092908A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862738508P 2018-09-28 2018-09-28
PCT/US2019/034653 WO2019232209A1 (en) 2018-05-30 2019-05-30 Ion channel modulators

Publications (1)

Publication Number Publication Date
EA202092908A1 true EA202092908A1 (ru) 2021-05-14

Family

ID=69949703

Family Applications (2)

Application Number Title Priority Date Filing Date
EA202092908A EA202092908A1 (ru) 2018-09-28 2019-05-30 Модуляторы ионных каналов
EA202190879A EA202190879A1 (ru) 2018-09-28 2019-09-27 Модуляторы ионных каналов

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA202190879A EA202190879A1 (ru) 2018-09-28 2019-09-27 Модуляторы ионных каналов

Country Status (12)

Country Link
US (1) US20210403476A1 (ru)
EP (1) EP3856193A4 (ru)
JP (2) JP2022502442A (ru)
KR (1) KR20210113974A (ru)
CN (1) CN113573713A (ru)
AU (1) AU2019346635A1 (ru)
BR (1) BR112021005913A2 (ru)
CA (1) CA3142470A1 (ru)
EA (2) EA202092908A1 (ru)
IL (1) IL281946A (ru)
MX (1) MX2021003634A (ru)
WO (1) WO2020069322A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110337295B (zh) 2016-11-28 2023-06-09 普拉克西斯精密药物股份有限公司 化合物以及它们的使用方法
US11261188B2 (en) 2016-11-28 2022-03-01 Praxis Precision Medicines, Inc. Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel
US11492345B2 (en) 2017-02-13 2022-11-08 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11731966B2 (en) 2017-04-04 2023-08-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11278535B2 (en) 2017-08-15 2022-03-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
SG11202011879RA (en) 2018-05-30 2020-12-30 Praxis Prec Medicines Inc Ion channel modulators
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
US11767325B2 (en) 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
TW202321263A (zh) 2021-08-10 2023-06-01 大陸商江蘇恆瑞醫藥股份有限公司 磺醯胺衍生物、其製備方法及其在醫藥上的應用
WO2024033374A1 (en) 2022-08-11 2024-02-15 Syngenta Crop Protection Ag Novel arylcarboxamide or arylthioamide compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4242515A (en) * 1979-03-28 1980-12-30 American Cyanamid Company Substituted 3-alkyl-6-phenyl-1,2,4-triazolo-[4,3-a]pyridines
US8952034B2 (en) * 2009-07-27 2015-02-10 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
WO2012065297A1 (en) * 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
CN110337295B (zh) * 2016-11-28 2023-06-09 普拉克西斯精密药物股份有限公司 化合物以及它们的使用方法

Also Published As

Publication number Publication date
CN113573713A (zh) 2021-10-29
US20210403476A1 (en) 2021-12-30
EP3856193A1 (en) 2021-08-04
IL281946A (en) 2021-05-31
MX2021003634A (es) 2021-07-16
BR112021005913A2 (pt) 2021-06-29
JP2022502442A (ja) 2022-01-11
EP3856193A4 (en) 2022-08-31
WO2020069322A1 (en) 2020-04-02
JP2024019735A (ja) 2024-02-09
KR20210113974A (ko) 2021-09-17
AU2019346635A1 (en) 2021-05-20
EA202190879A1 (ru) 2021-08-16
CA3142470A1 (en) 2020-04-02

Similar Documents

Publication Publication Date Title
EA202190879A1 (ru) Модуляторы ионных каналов
MX2020012838A (es) Moduladores de los canales ionicos.
MX2022006317A (es) Moduladores de canales iónicos.
MX2022006452A (es) Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos.
PH12018502258A1 (en) Isoquinolin-3-yl carboxamides and preparation and use thereof
EA201990187A1 (ru) Антипролиферационные средства на основе пиримидина
EA201991553A1 (ru) (аза)индол-, бензотиофен- и бензофуран-3-сульфонамиды
EA201891565A1 (ru) Соединения и композиции для лечения состояний, ассоциированных с активностью sting
PH12018501288A1 (en) Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels
EA201591746A1 (ru) Способы и композиции для ингибирования бромодомен-содержащих белков
MY184882A (en) Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathyway inhibitors
EA202092086A1 (ru) Ингибиторы аргиназы
PH12020552092A1 (en) Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease
PH12017502123A1 (en) Substituted benzamides and methods of use thereof
EA202090414A1 (ru) Соединения и их применение
MX2010010303A (es) Nuevos compuestos de acido ribonucleico de pequeña interferencia para inhibir rtp801.
EA201890090A1 (ru) Производные бензодиазепина, композиции и способы для лечения когнитивного нарушения
EA201891469A1 (ru) Агонист длительного действия glp-1r как терапия для лечения неврологических и нейродегенеративных патологических состояний
EA201590379A1 (ru) Пирролопиразолы, используемые в качестве блокаторов кальциевых каналов n-типа
MX2022000492A (es) Formulaciones de moduladores de canal de calcio tipo t y metodos de uso de estos.
MX2020005545A (es) Compuestos para el tratamiento de trastornos neuromusculares.
AU2020264106A8 (en) Small molecule bromodomain inhibitors and uses thereof
AU2017259966A1 (en) TrkB agonist antibodies for treating neurodegenerative disorders
EA202190298A1 (ru) Циклические динуклеотиды в качестве агонистов sting
EA202090555A1 (ru) Фармацевтические композиции, содержащие антитела к бета-амилоиду